Hepatocellular Cancer

News alerts, weekly reports and conference planners

No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 3 weeks (New B) bevacizumab + atezolizumab Sensitive : A1 Businesswire - 3wk	bevacizumab + atezolizumab Sensitive: A1 - Approval Businesswire - 3 weeks bevacizumab + atezolizumab Sensitive : A1 Businesswire - 3 weeks - (New B)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 3 weeks (New B) sorafenib Sensitive : A1 ASCO-GI 2023 - 3wk	sorafenib Sensitive: A1 - Approval ASCO-GI 2023 - 3 weeks sorafenib Sensitive : A1 ASCO-GI 2023 - 3 weeks - (New B)
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1	cabozantinib tablet Sensitive: A1 - Approval cabozantinib tablet Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1	sintilimab + Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval sintilimab + Byvasda (bevacizumab biosimilar) Sensitive : A1
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1	ramucirumab Sensitive: A1 - Approval ramucirumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1	lenvatinib Sensitive: A1 - Approval lenvatinib Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1	nivolumab + ipilimumab Sensitive: A1 - Approval nivolumab + ipilimumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1	tislelizumab Sensitive: A1 - Approval tislelizumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1	durvalumab Sensitive: A1 - Approval durvalumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1	durvalumab + tremelimumab Sensitive: A1 - Approval durvalumab + tremelimumab Sensitive : A1
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2	nivolumab Sensitive: A2 - Guideline nivolumab Sensitive : A2
NTRK3 fusion	Hepatocellular Cancer	NTRK3 fusion	Hepatocellular Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Hepatocellular Cancer	NTRK2 fusion	Hepatocellular Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Hepatocellular Cancer	NTRK1 fusion	Hepatocellular Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Hepatocellular Cancer	NTRK3 fusion	Hepatocellular Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Hepatocellular Cancer	NTRK2 fusion	Hepatocellular Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Hepatocellular Cancer	NTRK1 fusion	Hepatocellular Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2	sirolimus Sensitive: A2 - Guideline sirolimus Sensitive : A2
MSI-H/dMMR	Hepatocellular Cancer	MSI-H/dMMR	Hepatocellular Cancer	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2	dostarlimab Sensitive: A2 - Guideline dostarlimab Sensitive : A2
RET fusion	Hepatocellular Cancer	RET fusion	Hepatocellular Cancer	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
AFP elevation	Hepatocellular Cancer	AFP elevation	Hepatocellular Cancer	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B	regorafenib Sensitive: B - Late Trials regorafenib Sensitive : B
FGF21-H	Hepatocellular Cancer	FGF21-H	Hepatocellular Cancer	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B	lenvatinib Sensitive: B - Late Trials lenvatinib Sensitive : B
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	SRF388 Sensitive: B - Late Trials SRF388 Sensitive : B	SRF388 Sensitive: B - Late Trials SRF388 Sensitive : B
HGF-H + VEGFA-H	Hepatocellular Cancer	HGF-H + VEGFA-H	Hepatocellular Cancer	erlotinib + sorafenib Resistant: B - Late Trials erlotinib + sorafenib Resistant : B	erlotinib + sorafenib Resistant: B - Late Trials erlotinib + sorafenib Resistant : B
VEGFA-H	Hepatocellular Cancer	VEGFA-H	Hepatocellular Cancer	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B	lenvatinib Resistant: B - Late Trials lenvatinib Resistant : B
HGF elevation	Hepatocellular Cancer	HGF elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
CXCL8 elevation	Hepatocellular Cancer	CXCL8 elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
MET elevation	Hepatocellular Cancer	MET elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
ANGPT2 elevation	Hepatocellular Cancer	ANGPT2 elevation	Hepatocellular Cancer	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B	cabozantinib tablet Resistant: B - Late Trials cabozantinib tablet Resistant : B
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	atezolizumab + cabozantinib tablet Sensitive: B - Late Trials atezolizumab + cabozantinib tablet Sensitive : B	atezolizumab + cabozantinib tablet Sensitive: B - Late Trials atezolizumab + cabozantinib tablet Sensitive : B
No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	TTI-101 oral Sensitive: B - Late Trials TTI-101 oral Sensitive : B	TTI-101 oral Sensitive: B - Late Trials TTI-101 oral Sensitive : B
FGFR2 fusion	Hepatocellular Cancer	FGFR2 fusion	Hepatocellular Cancer	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1	infigratinib Sensitive: C1 - Off-label infigratinib Sensitive : C1

Hepatocellular Cancer

Associations(222)

Associations
(222)